Pfizer Profit Triples; Kerkorian Dumps Ford; U.S. Bancorp Profit Nearly Halved; Oil Back Below $72; Avigen’s Drug Trial Mishap; OceanFreight Sails to Strong Dividend; Copper’s Costly Tumble; McClatchy’s Slack Ad Sales

India is already renowned for being a pharmaceutical giant. But China could steal that crown within a decade. This could provide investors a ground-floor opportunity to make huge profits from IPOs, says Irwin Greenstein.

Slim Bites Into Big Apple Daily; Campbell’s Earnings Mmm, Mmm Good; King’s Alpharma Bid Heats Up; Conflicting Crude Trader Findings; WSJ: BAC to Buy Lehman; Bristol Doesn’t Budge; Sun Setting on Sunrise; Deutsche Bank Ready to Compete for Postbank

Marc Lichtenfeld at The Smart Profits Report says he’s found an “immense” investment opportunity in a small-cap biotech firm.

There are three entry points in biotech stocks. They are: The first stages of research for a new drug; the initial human trial phases; and immediately before the drug is FDA approved. The later the entry point, the safer the investment.

The stock Marc has his eye on is a late-stage company. It is finishing Phase III trials for a unique cancer treatment drug which, if successful, will corner an entire market.

Last May, shares of Regeneron Pharmaceuticals (REGN), a billion-dollar biotech, slid 35% in just 30 days. The company had no press releases, no earnings reports, nothing.

Within the first few months of 2008, shares of a billion-dollar biotech ran back and forth between $20 and $30… losing 50% one week only to pick it back up the next.

Back in December, my friend Steve Sjuggerud described a British spending spree taking place in America. At the time, the pound was worth about $1.95, and Brits were enjoying a 50% discount on their Christmas shopping across the pond.

Some sectors lend themselves beautifully to trend-following techniques. Biotechnology, for example, is a sector that goes through huge booms and busts. The reason is simple: New, world-changing technologies are a sexy story.

In 2002, Alkermes thought it had a winner on its hands… The small biotech and its Big Pharma partner, Johnson & Johnson, had developed the drug Risperdal Consta to combat schizophrenia. It was a great deal for a while… The market assumed the drug would be approved by the FDA the first time around.